Brief: Innate Pharma Presents Preliminary Data From Tellomak Trial Showing Clinical Response For Lacutamab In Mycosis Fungoides

Innate Pharma SA

22/06/2021 12:08

June 22 (Reuters) - Innate Pharma SA  IPH.PA :
    * INNATE PHARMA PRESENTS PRELIMINARY DATA FROM TELLOMAK
TRIAL
SHOWING CLINICAL RESPONSE FOR LACUTAMAB IN MYCOSIS FUNGOIDES
    * INNATE PHARMA - FIRST DATA SET FROM TELLOMAK ESTABLISHES
SAFETY,
CLINICAL RESPONSES & SKIN IMPROVEMENT IN PATIENTS WITH MYCOSIS
FUNGOIDES THAT EXPRESS KIR3DL2
    * INNATE PHARMA SA - DATA SUPPORT CONTINUED DEVELOPMENT OF
LACUTAMAB FOR KIR3DL2-EXPRESSING T-CELL LYMPHOMAS
    * INNATE PHARMA - LACUTAMAB SHOWED CLINICAL RESPONSES IN
PATIENTS
WITH MF THAT EXPRESS KIR3DL2 (COHORT 2), REACHING PRE-DETERMINED
THRESHOLD TO ADVANCE TO STAGE 2
    * INNATE PHARMA SA - IN LINE WITH PREVIOUS OBSERVATIONS,
LACUTAMAB
DEMONSTRATED A FAVORABLE SAFETY PROFILE IN MF

Source text for Eikon:  ID:nGNX9Hj9Pm 
Further company coverage:  IPH.PA 

 ((reuters.briefs@thomsonreuters.com;))